JP2018515071A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515071A5
JP2018515071A5 JP2017554283A JP2017554283A JP2018515071A5 JP 2018515071 A5 JP2018515071 A5 JP 2018515071A5 JP 2017554283 A JP2017554283 A JP 2017554283A JP 2017554283 A JP2017554283 A JP 2017554283A JP 2018515071 A5 JP2018515071 A5 JP 2018515071A5
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017554283A
Other languages
English (en)
Japanese (ja)
Other versions
JP6720208B2 (ja
JP2018515071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/058135 external-priority patent/WO2016166169A1/en
Publication of JP2018515071A publication Critical patent/JP2018515071A/ja
Publication of JP2018515071A5 publication Critical patent/JP2018515071A5/ja
Application granted granted Critical
Publication of JP6720208B2 publication Critical patent/JP6720208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017554283A 2015-04-17 2016-04-13 C4.4aを検出するための抗体、組成物、及び免疫組織化学法 Active JP6720208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149239P 2015-04-17 2015-04-17
US62/149,239 2015-04-17
PCT/EP2016/058135 WO2016166169A1 (en) 2015-04-17 2016-04-13 Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Publications (3)

Publication Number Publication Date
JP2018515071A JP2018515071A (ja) 2018-06-14
JP2018515071A5 true JP2018515071A5 (enExample) 2019-03-07
JP6720208B2 JP6720208B2 (ja) 2020-07-08

Family

ID=55702016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554283A Active JP6720208B2 (ja) 2015-04-17 2016-04-13 C4.4aを検出するための抗体、組成物、及び免疫組織化学法

Country Status (6)

Country Link
US (2) US10948493B2 (enExample)
EP (1) EP3283522A1 (enExample)
JP (1) JP6720208B2 (enExample)
AU (1) AU2016249839B2 (enExample)
CA (1) CA2982536C (enExample)
WO (1) WO2016166169A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技(上海)有限公司 糖基磷脂酰肌醇锚定糖蛋白(c4.4a)的单克隆抗体及其应用
WO2022261403A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof
AU2023234686A1 (en) * 2022-03-16 2024-08-29 Pentixapharm Ag Antibodies against lypd3
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN116086919B (zh) * 2023-02-20 2024-01-26 深圳裕策生物科技有限公司 一种肺癌和/或胰腺癌样本的染色方法及试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023553A2 (en) 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
ATE556845T1 (de) 2001-07-20 2012-05-15 Life Technologies Corp Lumineszierende nanopartikel und ihre herstellung
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
US7632652B2 (en) 2003-06-24 2009-12-15 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
DK2078197T3 (en) 2006-11-01 2016-05-23 Ventana Med Syst Inc Haptenes, hapten conjugates, compositions thereof and processes for their preparation and use
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
ES2667729T3 (es) * 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
JP5989544B2 (ja) * 2009-12-09 2016-09-07 バイエル・ファルマ・アクティエンゲゼルシャフト 抗C4.4a抗体およびその使用
JP5881604B2 (ja) 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
TWI582112B (zh) * 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑-藥物接合物(ADCs)及其用途(二)
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
WO2012158780A2 (en) 2011-05-16 2012-11-22 The Regents Of The University Of Michigan Lung cancer signature
KR20150013935A (ko) 2012-06-08 2015-02-05 갓코 호진 긴키 다이가쿠 트랜스포터에 대한 항체 및 이의 용도
WO2014183119A1 (en) 2013-05-10 2014-11-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging probes for lung cancer inoperative guidance
US20160115237A1 (en) * 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
AU2015315332A1 (en) * 2014-09-09 2017-03-30 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Similar Documents

Publication Publication Date Title
JP2018515071A5 (enExample)
CN109265548B (zh) 抗pd-l1纳米抗体及其编码序列、制备方法和应用
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
ES2342646B1 (es) Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
JP2020522261A5 (enExample)
JP2015533788A5 (enExample)
PE20071055A1 (es) Anticuerpos anti mn
JP2018536393A5 (enExample)
JP2020526478A5 (enExample)
JP2017518366A5 (enExample)
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
JP2021500916A5 (enExample)
RU2015103228A (ru) Антитела против тау
JP2015531768A5 (enExample)
JP2016536330A5 (enExample)
JP2017508475A5 (enExample)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2015527365A5 (enExample)
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
JP2018535404A5 (enExample)
JP2015517982A5 (enExample)
CA3093008C (en) Monoclonal antibodies that bind to the embryonic stage-specific antigen 4 and their uses
JP2018520668A5 (enExample)
JP2020510409A5 (enExample)
MX2017004970A (es) Anticuerpos que se unen a ccr6 y sus usos.